Severity
Moderate
FDA Drug recall · Reported June 15, 2022
cGMP deviations: Temperature abuse
Mckesson Medical-Surgical Inc. Corporate Office recalled Meclizine Hydrochloride Tablets, USP, 25 mg, 50-count cartons (5 x10 unit dose), 10 Table… - a moderate-severity action.
Meclizine Hydrochloride Tablets, USP, 25 mg, 50-count cartons (5 x10 unit dose), 10 Table… was recalled by Mckesson Medical-Surgical Inc. Corporate Office in June 15, 2022. Reason: cGMP deviations: Temperature abuse. Check the official notice for the remedy. Verify recall #D-1037-2022 with the FDA Drug before acting.
The recall
Mckesson Medical-Surgical Inc. Corporate Office issued this moderate-severity FDA Drug recall-cGMP deviations: Temperature abuse.
Sourced from official FDA Drug enforcement records. Verify recall #D-1037-2022 with the agency before acting. Full product description, hazard, remedy, and related recalls are below.
This FDA Drug action (record #D-1037-2022) was formally reported on June 15, 2022, with the manufacturer initiating the action on April 13, 2022. It is classified under Moderate severity (Class II), with a current status of Terminated. Mckesson Medical-Surgical Inc. Corporate Office is listed as the recalling firm, operating out of Richmond, VA. Federal records list the affected scope as 1 box/50 blister packs per box.
The documented reason for this recall is: cGMP deviations: Temperature abuse Distribution data in the federal record shows the product reached: USA nationwide.. Distribution scope directly affects the consumer exposure window and determines whether a recall remains regional or escalates into a nationwide advisory.
Within the same product category the archive holds 6 closely related recalls, 5 from FDA Drug - clustering in a narrow category often points to a systemic quality-control or supplier issue rather than a one-off defect. Always verify the recall number against the official agency record before acting.
Where this recall sits in its category - 14,287 drugs & medications recalls on record
Of 101,704 recalls in the database, 24,878 are high severity, 72,426 moderate, and 4,400 low. This recall is classified moderate severity.
Counts reflect market size and reporting activity, not inherent danger, we do not rank products by risk from raw recall volume.
Severity
Moderate
Affected scope
1 box/50 blister packs per box
Related Recalls
6
5 from same agency
Meclizine Hydrochloride Tablets, USP, 25 mg, 50-count cartons (5 x10 unit dose), 10 Tablets per card, 5 cards per carton, Rx only, MFG: Avkare Inc., NDC 50268-523-15
cGMP deviations: Temperature abuse
| Attribute | Value |
|---|---|
| Agency | U.S. Food and Drug Administration |
| Severity class | Moderate (Class II) |
| Status | Terminated |
| Recall number | D-1037-2022 |
| Date reported | June 15, 2022 |
| Date initiated | April 13, 2022 |
| Recalling firm | Mckesson Medical-Surgical Inc. Corporate Office |
| Firm location | Richmond, VA |
| Affected scope | 1 box/50 blister packs per box |
| Distribution | USA nationwide. |
Profile values are sourced directly from the official FDA Drug enforcement record. Source: U.S. Food and Drug Administration.
What to do with this recall
Match your product against the recall record, then act on the agency remedy.
This page summarizes the official FDA Drug record for research and awareness; it is not legal, medical, or safety advice. Verify with the issuing agency before acting.
Other recalls in the same product category, useful for spotting patterns across the same defect class or manufacturer.
AbbVie Inc. · 2026-06-03
Llorens Pharmaceuticals International Division, Inc. · 2026-05-27
Safecor Health, LLC · 2026-05-27
IntegraDose Compounding Services LLC · 2026-05-27
Lupin Pharmaceuticals Inc. · 2026-05-27
Compare this recall with PRED MILD, prednisolone acetate ophthalmic suspension, USP,… →
Every figure on PlainRecalls is rendered directly from official FDA, CPSC and NHTSA recall records, no number is typed in by an editor. This recall: FDA Drug, reported June 15, 2022. Severity classes follow each agency's own taxonomy (FDA Class I/II/III; CPSC and NHTSA by hazard type), and related-recall context is computed across the full archive. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of July 2026.